title: Preliminary evaluation of the in vitro efficacy of 1, 2-di (quinazolin-4-yl) diselane against SiHa cervical cancer cells.
abstract: Cervical cancer is one the most common malignancies among females. In recent years, its incidence rate has shown a rising trend in some countries so that development of anticancer drugs for cervical cancer is an urgent priority. In our recent anticancer drug discovery screen, 1, 2-di (quinazolin-4-yl)diselane (LG003) was found to possess wide spectrum anticancer efficacy. In the present work, the in vitro anticancer activity of LG003 was evaluated in the SiHa cervical cancer cell line. Compared with commercial anticancer drugs 10-hydroxycamptothecin, epirubicin hydrochloride, taxol and oxaliplatin, LG003 showed better anticancer activity. Furthermore, inhibition effects were time- and dose-dependent. Morphological observation exhibited LG003 treatment results in apoptosis like shrinking and blebbing, and cell membrane damage. Lactate dehydrogenase release assay revealed that LG003 exerts such effects in SiHa cells through a physiology pathway rather than cytotoxicity, which suggests that title compound LG003 can be a potential candidate agent for cervical cancer.
authors.affiliation: Department of Bioscience, Bengbu Medical College, Bengbu, China E-mail : gangliu1977@163.com, zhyy8727@126.com.
authors.forename: Yin-Jiu
authors.initials: YJ
authors.lastname: Huang
authors.forename: Yu-Yuan
authors.initials: YY
authors.lastname: Zhang
authors.forename: Gang
authors.initials: G
authors.lastname: Liu
authors.forename: Jie
authors.initials: J
authors.lastname: Tang
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Hu
authors.forename: Zhen-Zhong
authors.initials: ZZ
authors.lastname: Feng
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.forename: Qi-Yi
authors.initials: QY
authors.lastname: Wang
authors.forename: Dan
authors.initials: D
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D016566:Organoselenium Compounds / Q000737:chemistry* / Q000494:pharmacology; D011799:Quinazolines / Q000737:chemistry* / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: C000613607:1,2-di(quinazolin-4-yl)diselane; D000970:Antineoplastic Agents; D016566:Organoselenium Compounds; D011799:Quinazolines; D007770:L-Lactate Dehydrogenase